JP2012509269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509269A5 JP2012509269A5 JP2011536560A JP2011536560A JP2012509269A5 JP 2012509269 A5 JP2012509269 A5 JP 2012509269A5 JP 2011536560 A JP2011536560 A JP 2011536560A JP 2011536560 A JP2011536560 A JP 2011536560A JP 2012509269 A5 JP2012509269 A5 JP 2012509269A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- antibody
- formulation
- seq
- full length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000858 Cyclodextrin Polymers 0.000 claims 42
- 238000000034 method Methods 0.000 claims 35
- 238000009472 formulation Methods 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 32
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 20
- 239000001116 FEMA 4028 Substances 0.000 claims 10
- 229960004853 betadex Drugs 0.000 claims 10
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 238000007920 subcutaneous administration Methods 0.000 claims 5
- BHKSYEZGBQDNRW-SCGRZTRASA-N C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O Chemical compound C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O BHKSYEZGBQDNRW-SCGRZTRASA-N 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 238000000502 dialysis Methods 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 229920002521 macromolecule Polymers 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 101000907840 Methylorubrum extorquens (strain ATCC 14718 / DSM 1338 / JCM 2805 / NCIMB 9133 / AM1) Glycerate dehydrogenase Proteins 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 238000011481 absorbance measurement Methods 0.000 claims 1
- 238000005054 agglomeration Methods 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940074409 trehalose dihydrate Drugs 0.000 claims 1
- 238000011179 visual inspection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11544108P | 2008-11-17 | 2008-11-17 | |
| US61/115,441 | 2008-11-17 | ||
| PCT/US2009/064610 WO2010057107A1 (en) | 2008-11-17 | 2009-11-16 | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015150264A Division JP2016020350A (ja) | 2008-11-17 | 2015-07-30 | 生理的条件下での高分子の凝集を低減するための方法及び製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509269A JP2012509269A (ja) | 2012-04-19 |
| JP2012509269A5 true JP2012509269A5 (cg-RX-API-DMAC7.html) | 2012-12-27 |
Family
ID=42170392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536560A Pending JP2012509269A (ja) | 2008-11-17 | 2009-11-16 | 生理的条件下での高分子の凝集を低減するための方法及び製剤 |
| JP2015150264A Pending JP2016020350A (ja) | 2008-11-17 | 2015-07-30 | 生理的条件下での高分子の凝集を低減するための方法及び製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015150264A Pending JP2016020350A (ja) | 2008-11-17 | 2015-07-30 | 生理的条件下での高分子の凝集を低減するための方法及び製剤 |
Country Status (17)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| JP5341059B2 (ja) * | 2010-11-09 | 2013-11-13 | 株式会社大塚製薬工場 | 幹細胞懸濁液 |
| WO2013164837A1 (en) * | 2012-03-07 | 2013-11-07 | Cadila Healthcare Limited | Pharmaceutical formulations of tnf-alpha antibodies |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| CA2901575C (en) | 2013-03-13 | 2022-08-30 | Seattle Genetics, Inc. | Cyclodextrin and antibody-drug conjugate formulations |
| SG11201804961UA (en) * | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
| GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| KR102039709B1 (ko) | 2017-11-03 | 2019-11-01 | 삼성전자주식회사 | 유기 인터포저를 포함하는 반도체 패키지 |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| EP4138888A1 (en) * | 2020-04-23 | 2023-03-01 | Eli Lilly and Company | Subcutaneous absorption and bioavailability of antibodies |
| RU2754509C1 (ru) * | 2020-12-21 | 2021-09-02 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ лечения первичной мембранозной нефропатии с нефротическим синдромом и повышенным уровнем анти-plar2 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5759573A (en) * | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP2000226336A (ja) * | 1998-11-30 | 2000-08-15 | Sankyo Co Ltd | 免疫グロブリン製剤 |
| CA2477857C (en) * | 1999-10-04 | 2012-04-10 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| DE10228049A1 (de) * | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004064787A2 (en) * | 2003-01-14 | 2004-08-05 | Teva Pharmaceutical Industries, Ltd. | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| JP4869064B2 (ja) * | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| NZ587776A (en) * | 2003-04-09 | 2012-03-30 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody |
| DE10361599A1 (de) * | 2003-12-24 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Flüssigformulierung von Antikörperkonjugaten |
| WO2005113592A2 (en) * | 2004-05-19 | 2005-12-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| NZ564843A (en) * | 2005-08-03 | 2012-05-25 | Immunogen Inc | Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution |
| MX2009006199A (es) * | 2006-12-11 | 2009-06-22 | Hoffmann La Roche | Formulacion parenteral de anticuerpos abeta. |
| CN101204374A (zh) * | 2006-12-18 | 2008-06-25 | 宜兴市天石饲料有限公司 | 一种包被复合型多价高效蛋黄抗体 |
| ES2750254T3 (es) * | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
-
2009
- 2009-11-16 AR ARP090104434A patent/AR074357A1/es unknown
- 2009-11-16 CN CN2009801546640A patent/CN102281903B/zh not_active Expired - Fee Related
- 2009-11-16 RU RU2011124550/15A patent/RU2563823C2/ru not_active IP Right Cessation
- 2009-11-16 PE PE2011001040A patent/PE20120169A1/es not_active Application Discontinuation
- 2009-11-16 MX MX2011005051A patent/MX2011005051A/es not_active Application Discontinuation
- 2009-11-16 JP JP2011536560A patent/JP2012509269A/ja active Pending
- 2009-11-16 EP EP09826919.4A patent/EP2358395A4/en not_active Withdrawn
- 2009-11-16 WO PCT/US2009/064610 patent/WO2010057107A1/en not_active Ceased
- 2009-11-16 BR BRPI0916072A patent/BRPI0916072A2/pt not_active IP Right Cessation
- 2009-11-16 KR KR1020117011124A patent/KR20110086705A/ko not_active Ceased
- 2009-11-16 CA CA2742988A patent/CA2742988A1/en not_active Abandoned
- 2009-11-16 TW TW098138926A patent/TW201032826A/zh unknown
- 2009-11-16 AU AU2009313754A patent/AU2009313754A1/en not_active Abandoned
-
2011
- 2011-04-20 ZA ZA2011/03006A patent/ZA201103006B/en unknown
- 2011-04-28 IL IL212533A patent/IL212533A0/en unknown
- 2011-05-13 US US13/107,137 patent/US20110305639A1/en not_active Abandoned
- 2011-05-16 CL CL2011001132A patent/CL2011001132A1/es unknown
-
2013
- 2013-06-10 US US13/914,094 patent/US20140093493A1/en not_active Abandoned
-
2015
- 2015-07-30 JP JP2015150264A patent/JP2016020350A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509269A5 (cg-RX-API-DMAC7.html) | ||
| RU2011124527A (ru) | Способ и композиция для уменьшения агрегации макромолекулы в физиологических условиях | |
| RU2011124550A (ru) | Способ и композиция для уменьшения агрегации макромолекул при физиологических условиях | |
| KR102671283B1 (ko) | 항tim-3 항체로 암을 치료하는 방법 | |
| ES3030036T3 (en) | Pharmaceutical compositions comprising secukinumab | |
| KR102606252B1 (ko) | 항-pd-1 항체로 암을 치료하는 방법 | |
| AU2017287743B2 (en) | Stable liquid pharmaceutical preparation | |
| ES2769123T3 (es) | Anticuerpos de quimiocinas PAN ELR+ CXC | |
| JP7266108B2 (ja) | 治療用抗体製剤 | |
| CN103119062A (zh) | 修饰的单结构域抗原结合分子及其应用 | |
| CA2922251C (en) | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics | |
| BR112021004649A2 (pt) | formulação farmacêutica e uso de uma formulação | |
| CN108367074A (zh) | 使用白介素-17（il-17）拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| BR112021005204A2 (pt) | formulações farmacêuticas e método para tratar um tumor sólido | |
| CN114502241A (zh) | 抗半乳凝素-9抗体和化疗剂的联合癌症疗法 | |
| EP4293045A1 (en) | Anti-tigit antibody pharmaceutical composition and application thereof | |
| CN112888711A (zh) | 基于flt3l的嵌合蛋白 | |
| EP3472202A1 (en) | Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease | |
| AU2013285970B2 (en) | Therapeutic method and remedy for HTLV-1-associated myelopathy patients | |
| JP2024075676A (ja) | Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療 | |
| TW201919697A (zh) | 用於治療ＴＮＦα相關的疾病之方法 | |
| CN116685352A (zh) | 用gm-csf拮抗剂治疗癌症 | |
| CN111420049A (zh) | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 | |
| JP7548475B1 (ja) | 抗体製剤 | |
| WO2025218746A1 (en) | Methods of treating rheumatoid arthritis |